Skip to content

Effect of Valerian on The Quality of Sleep and Anxiety in Patients with MS

Effect of Valerian on The Quality of Sleep and Anxiety in Patients with MS

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT2017070531348N2
Enrollment
46
Registered
2017-09-15
Start date
2016-11-21
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

MS. Demyelinating diseases of the central nervous system

Interventions

Intervention 1: Intervention group: Patients in the intervention group used tea bags of valerian at a dose of 2 grams per night for 30 to 90 minutes before bedtime and for 21 nights and put one tea i
Treatment - Drugs
Intervention group: Patients in the intervention group used tea bags of valerian at a dose of 2 grams per night for 30 to 90 minutes before bedtime and for 21 nights and put one tea in a glass of bo
control group: In the same package, the intervention group consisted of wheat flour, tafted with red sugar, at 2 grams per night for 30 to 90 minutes befor bed time and for 21 nights and put one it

Sponsors

University Of Social Welfare And Rehabilitation Sciences
Lead Sponsor
University of Social Welfare and Rehabilitation
Collaborator

Eligibility

Sex/Gender
All
Age
75 Years to 55 Years

Inclusion criteria

Inclusion criteria: Entry Criteria: Confirmation of MS by the center's neurologist; The absence of other neurological disorders and mental and mental disorders, according to the patient's case and opinion; At least six months of diagnosis; Having reading and writing skills or having a companion to complete; the person questionnaire in the age range of 20-45 years; Failure to have liver disease or deficiency in liver enzymes, lack of pregnancy and lactation; Failure to receive complementary and alternative therapies during the past three months. (To reduce anxiety and improve sleep quality.) Exit criteria: No patient incentive to continue cooperation. During the research; To perform this intervention in the past (because of the decrease in the amount of suppression, the probability of answering the questions based on the information stored in the previous study); Not having enough insight into the disease and not having the ability to collaborate in the study; Drug use New sedative and hypnotic; Alcohol users, Barbiturates and Benzodiazepine (in iron users between consumption Valerie N and iron should be 1 to 2 hours apart); Hepatitis and pregnancy ; If not used for 2 days

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Sleep Quality, Anxiety. Timepoint: Befor Intervention- After Intervention. Method of measurement: Questionnaire.

Secondary

MeasureTime frame
Improve The Quality of Sleep, Reduce Anxiety. Timepoint: Before The Intervention - After The End of Intervention. Method of measurement: Questionnaire.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMahdieh Sedighi Pashaki

Univercity of Social Walfare and Rehabilitation Science

mahdieh.sedighi@gmail.com+98 21 4684 0377

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026